NASCOPhttps://www.nascop.or.ke
National AIDS & STI Control ProgrammeMon, 28 Jan 2019 08:25:02 +0000en-UShourly1https://wordpress.org/?v=4.7.4Pre Exposure Prophylaxis for HIV (Oral PrEP)https://www.nascop.or.ke/?p=2709
Sat, 06 May 2017 13:35:15 +0000http://www.nascop.or.ke/?p=2709More than two million people acquire HIV infection globally every year. In Kenya, 71,034 people aged above 15 years and 6,613 aged 0-14 years got infected with HIV in 2015. This means that these 77, 648 Kenyans would require lifelong antiretroviral treatment to keep them alive and prevent further transmission of HIV.

In September 2015, the WHO issued a strong recommendation for Pre-­exposure prophylaxis (PrEP) recommending use of antiretroviral drugs to prevent acquisition of HIV infection. Subsequently, in July 2016, The Ministry of Health – Kenya, released HIV treatment and prevention guidelines recommending provision of immediate initiation of ART and PrEP use among the uninfected partners at high risk of HIV acquisition. These interventions will contribute to achievement of the objectives laid out in the Kenya AIDS Strategic Framework 2014/15-2018/19 and the HIV Prevention Revolution Road Map to reduce new HIV infections.

The Vision, Goal and Mission of PrEP Implementation in Kenya

Pre Exposure Prophylaxis(PrEP) is a new prevention method for HIV negative people that has been introduced in Kenya. We aim to prevent HIV infections to all people at substantial ongoing risk of HIV and improve their quality of life.

The Focus Areas and Objectives of the PrEP program

Policies however have the potential to change the HIV landscape by including Treatment as prevention and introducing PrEP. In September 2015, the WHO issued a strong recommendation for Pre-­exposure prophylaxis (PrEP) recommending use of antiretroviral drugs to prevent acquisition of HIV infection. Subsequently, in July 2016, The Ministry of Health – Kenya, released HIV treatment and prevention guidelines recommending provision of immediate initiation of ART and PrEP use among the uninfected partners at high risk of HIV acquisition. These interventions will contribute to achievement of the objectives laid out in the Kenya AIDS Strategic Framework and the HIV Prevention Revolution Road Map to reduce new HIV infections.

PrEP Journey in Kenya

There has been various demonstration projects of administering oral PrEP to serodiscordant couples, heterosexual women and populations at high risk of being infected with HIV

PrEP is incorporated into the Kenyan HIV Prevention Revolution Roadmap and is also identified as an evidence-based intervention in the most recent Kenya AIDS Strategic Framework (KASF). PrEP is also included in the Guidelines on use of ARV drugs for treating and preventing HIV infections in Kenya – 2016 edition

National PrEP roll out

The government will roll out the use of PrEP across the country making it accessible to Kenyans who require it to prevent themselves from the risk of acquiring HIV

]]>Publications & Citationshttps://www.nascop.or.ke/?p=1884
Thu, 28 Jan 2016 07:04:24 +0000http://nascop.or.ke/?p=1884Note: If you would like to quote any of our publications or citations kindly reference the Source documents.
Please browse to the page to see this content.

Recommendations for Use of Anti retro-viral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission.

Questions about HIV treatment and research.

Latest HIV/AIDS related news.

CME’s on HIV

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.Read More…

UPTODATE

Smarter Decisions. Better Care.
UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care.
It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes.Read More…

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and treatment recommendations occur.Read More…

HIV DRUG INTERACTIONS

In HIV therapy, patients take more than one antiretroviral medication at a time and possibly other drugs to treat co-existing conditions. Many of the drug combinations have the potential to interact and this can affect either the patient’s safety or the effectiveness of treatment. For this reason some drug combinations should not be given at all, while other drugs may be used together with caution, possibly requiring adjustments to dosage or time of administration.Read More…

Clinical Care Options believes the way to optimize clinicians’ competence in providing the highest standards of evidence-based medicine are through effective education and the availability of the latest clinical information, whenever and wherever it is needed. CCO is dedicated to improving patient care by providing superior-quality, relevant educational content and clinical knowledge as delivered through its innovative and integrated online and mobile platforms, which provide comprehensive and personalized information solutions.Read More…

HIVdb accepts user-submitted protease and RT sequences and returns inferred levels of resistance to 19 commonly used protease and RT inhibitors. Its purpose is educational and as such it provides extensive comments and a highly transparent scoring system that is hyperlinked to data in the HIV Drug Resistance Database.Read More…

Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children.
Read More…

A current list of mutations associated with clinical resistance to HIV and the accompanying user notes, which are regularly revised and disseminated by the IAS–USA Drug Resistance Mutations Group, is published in Topics in Antiviral Medicine™ (formerly Topics in HIV Medicine®). The figures are also available as downloadable PDF and PowerPoint files.Read More…